Rani Therapeutics Holdings, Inc.
RANI
Rank in Stocks
#23929
Rani Therapeutics Holdings, Inc. functions as a clinical-stage... Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant conventional subcutaneous or intravenous injections of biologics with a more convenient oral dosing method. The company maintains a comprehensive portfolio of investigational treatments. Among these is RT-101, an octreotide, which has progressed beyond Phase I clinical trials for the management of neuroendocrine tumors and acromegaly. Another promising candidate is RT-105, an anti-TNF-alpha antibody designed to address psoriatic arthritis. Additionally, RT-102, a parathyroid hormone for osteoporosis, is currently advancing through preclinical studies. Other therapies under development include RT-109, a human growth hormone for treating growth hormone deficiency; RT-110, a parathyroid hormone aimed at hypoparathyroidism; and RT-106, a basal insulin formulated for type 2 diabetes. Established in 2012, the company's corporate base is located in San Jose, California.
Share Price
$0.5743
Last synced: 2026-11-09
Market Cap
$37.51M
Change (1 day)
5.03%
Change (1 year)
-70.40%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Rani Therapeutics Holdings, Inc. (RANI)
Category
Healthcare
Operating Margin for Rani Therapeutics Holdings, Inc. (RANI)
Operating Margin as of November 2026 TTM: -675.80%
According to Rani Therapeutics Holdings, Inc.'s latest financial reports, its current operating margin (TTM) is -675.80%. At the end of 2025 the company had an operating margin of -2,345.99%.
Operating Margin history for Rani Therapeutics Holdings, Inc. from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -675.80% | -71.19% |
| 2025 | -2,345.99% | -54.76% |
| 2024 | -5,186.19% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | -100.00% |
| 2021 | -1,899.12% | -46.97% |
| 2020 | -3,580.95% | 29.53% |
| 2019 | -2,764.56% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.06% |
US
|
|
| -149.01% | -99.78% |
US
|
|
| 25.57% | -100.04% |
AU
|
|
| 31.23% | -100.05% |
BE
|
|
| 29.35% | -100.04% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Rani Therapeutics Holdings, Inc.'s operating margin
What is Rani Therapeutics Holdings, Inc.'s operating margin?
Rani Therapeutics Holdings, Inc.'s operating margin is -675.80%, as of Nov 2026.
What was Rani Therapeutics Holdings, Inc.'s operating margin in 2025?
In 2025, Rani Therapeutics Holdings, Inc.'s operating margin was -2,345.99%, compared with -5,186.19% in 2024.
How has Rani Therapeutics Holdings, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Rani Therapeutics Holdings, Inc.'s operating margin was highest in 2023 (0.00%) and lowest in 2024 (-5,186.19%).
How does Rani Therapeutics Holdings, Inc.'s operating margin compare with similar companies?
Rani Therapeutics Holdings, Inc.'s operating margin (-675.80%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.